Welcome to our dedicated page for Applied Dna Scie SEC filings (Ticker: APDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The APDN SEC filings archive on Stock Titan provides access to the historical regulatory documents of Applied DNA Sciences, Inc., which has since changed its name to BNB Plus Corp. and its Nasdaq trading symbol to BNBX. These filings document the company’s evolution from a biotechnology issuer focused on PCR-based DNA technologies and nucleic acid production solutions to an issuer that also pursues a BNB-focused digital asset treasury strategy.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, including its LineaDNA, LineaRNAP, and LineaIVT platforms, segment information, and financial statements. Current reports on Form 8-K capture material events such as strategic restructurings, workforce reductions, the wind down of DNA tagging and security products and services, the cessation of Applied DNA Clinical Labs operations, reverse stock splits, private placement transactions, at-the-market offering agreements, and the initiation of the BNB-focused treasury strategy.
Filings also include proxy materials (DEF 14A) that describe proposals such as increasing authorized shares of common stock and amending the company’s equity incentive plan, along with information on corporate governance and executive compensation. Additional registration statements, including shelf registrations and related prospectus supplements, outline the company’s approaches to raising capital through equity offerings and warrant issuances.
On Stock Titan, these APDN filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand topics such as segment realignments, digital asset management agreements with Cypress LLC and Cypress Management LLC, and changes in corporate name and ticker symbol. Real-time connections to the SEC’s EDGAR system support timely updates as new filings are made under the company’s current identity, BNB Plus Corp. (BNBX). Users can also examine insider-related disclosures and warrant arrangements where reported, gaining a clearer view of historical capital structure and governance decisions linked to the former APDN symbol.
Applied DNA Sciences disclosed an insider equity award. On 10/17/2025, Chief Financial Officer Beth Jantzen acquired 18,691 shares reported as common stock at $0 per share, tied to a restricted stock unit grant. The filing states 100% of the RSUs vest 90 days from the grant date. Following this grant, her beneficial ownership stood at 18,694 shares, held directly.
Applied DNA Sciences reported an insider transaction on a Form 4. A director received 22,511 shares of common stock on 10/17/2025, listed with Transaction Code "A" at a price of $0.
Following this award, the reporting person beneficially owned 22,512 shares held directly. The filing notes the grant is in the form of restricted stock units that vest 100% after 90 days from the date of grant.
Applied DNA Sciences filed a Form 4 showing a director acquired 22,511 shares of common stock at $0 on 10/17/2025. Following the transaction, the director beneficially owns 22,512 shares, held directly. The filing notes that 100% of the related restricted stock units vest 90 days from the date of grant.
Applied DNA Sciences reported an insider equity change on a Form 4. A director acquired 18,691 shares of common stock on 10/17/2025 with a reported price of $0 (transaction code A). Following the transaction, the reporting person beneficially owns 18,694 shares, held directly.
The filing notes that 100% of the restricted stock units vest upon 90 days from the date of grant, indicating the award structure tied to service over a short vesting period.
Applied DNA Sciences reported an insider equity change. The Chief Executive Officer filed a Form 4 showing acquisition of 18,691 shares of common stock on 10/17/2025 at a price of $0, coded “A.” Following the transaction, the officer beneficially owned 18,695 shares, held directly.
The filing notes that 100% of the related restricted stock units vest 90 days from the date of grant.
Applied DNA Sciences announced a corporate restructuring to refocus resources on a BNB-focused treasury strategy. The company will cut its workforce by 16 employees, about
Applied DNA Sciences, Inc. (APDN) filed a Form 8-K disclosing a set of exhibits dated September 29, 2025. The filing lists forms of financing and related documents, including cash and cryptocurrency securities purchase agreements, multiple warrant forms (prefunded, common, cryptocurrency, advisory, and placement agent warrants), registration rights agreements, and a Strategic Digital Asset Services Agreement plus a related Strategic Advisor Agreement with Cypress entities. The exhibit list also includes employment and separation agreements, a press release, a supplemental business description, and supplemental risk factors. These exhibits indicate contemporaneous arrangements covering securities issuance mechanics, digital-asset-related services/advisory support, and personnel agreements that could affect corporate structure and capitalization.
Applied DNA Sciences, Inc. entered a three-year consulting and sponsorship arrangement through September 23, 2028, under which a named Consultant will provide advisory and marketing services and deliver premium sponsorship benefits at all SALT conferences globally for 36 months.
The Company will pay the Consultant a total upfront/contracted fee structure including $1,000,000 and additional amounts of $250,000 paid quarterly from December 2025 until September 2027. Immediately following the closing of the referenced Offering, the Consultant will receive warrants exercisable for a number of common shares equal to 1% of the fully diluted outstanding equity of the Company as of immediately after that closing. The Consultant Warrants have an exercise price equal to 115% of the per-share purchase price under the Securities Purchase Agreement, are exercisable for cash for five years, and may be exercised on a cashless basis beginning six months after issuance if resale registration is not available.
The filing is signed by Clay Shorrock, Chief Executive Officer.
Applied DNA Sciences, Inc. has a Schedule 13G reporting that three related reporting persons—Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC—may be deemed to beneficially own 143,336 shares of common stock, representing 9.99% of the common stock on a diluted basis. The filing explains those shares are issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 1") and notes blocker provisions that limit exercise to avoid exceeding 9.99% (and a second warrant with a 4.99% blocker). The report lists shared voting and dispositive power over the 143,336 shares and provides addresses and citizenship of the reporting persons. The filing includes signed certifications and a joint filing agreement.
Applied DNA Sciences (APDN) discloses that a group of affiliated investment entities and individuals led by Anson controls 573,538 shares, representing 8.2% of the outstanding common stock on a diluted basis including warrants. The filing states the position is held in the ordinary course of business and not for the purpose of changing control. Shared voting and dispositive power over the 573,538 shares is reported, with no sole voting or dispositive power claimed. The filing identifies the reporting persons and their organizational domiciles and clarifies warrant exercise limitations considered in the ownership percentage.
FAQ
What is the current stock price of Applied Dna Scie (APDN)?
What is the market cap of Applied Dna Scie (APDN)?
